Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 2Genitourinary 1

Conditions

Ovarian Neoplasms 2Neuralgia 1Breast Neoplasms 1

Interventions

Paclitaxel 575Carboplatin 521Cisplatin 351Bevacizumab 252pembrolizumab 228Gemcitabine 157Topotecan 128Cyclophosphamide 128liposomal doxorubicin 127olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 81niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 57Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Telmisartan × Gynecologic × Clear all
NCT06815497 2026-01-28

Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer

Dartmouth-Hitchcock Medical Center

Phase 2 Recruiting
33 enrolled
Gynecologic

Ovarian Neoplasms

NCT05322889 2024-08-28

PrevTel

Fraunhofer Institute for Translational Medicine and Pharmacology ITMP

Phase 2 Completed
35 enrolled
BreastGynecologic

Breast Neoplasms, Neuralgia, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡